Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics
Cumberland Pharmaceuticals Inc. (CPIX)
Today's Latest Price: $3.24 USD
Updated Jan 15 3:59pm
Add CPIX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CPIX Stock Summary
- With a market capitalization of $49,200,525, Cumberland Pharmaceuticals Inc has a greater market value than only 10.87% of US stocks.
- In terms of volatility of its share price, CPIX is more volatile than just 15% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CPIX comes in at 11.08% -- higher than that of 84.33% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Cumberland Pharmaceuticals Inc are BLIN, DOGZ, NSPR, FEIM, and OBLG.
- CPIX's SEC filings can be seen here. And to visit Cumberland Pharmaceuticals Inc's official web site, go to www.cumberlandpharma.com.
CPIX Stock Price Chart Interactive Chart >
CPIX Price/Volume Stats
| Current price | $3.24 | 52-week high | $5.23 |
| Prev. close | $3.25 | 52-week low | $2.77 |
| Day low | $3.22 | Volume | 18,600 |
| Day high | $3.28 | Avg. volume | 21,380 |
| 50-day MA | $3.02 | Dividend yield | N/A |
| 200-day MA | $3.30 | Market Cap | 48.66M |
Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
CPIX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $3.24 | $1.09 | -66% |
Below please find a table outlining a discounted cash flow forecast for CPIX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 72. Its equity weight surpasses that of only 23.83% of free cash flow generating stocks in the Healthcare sector.
- Cumberland Pharmaceuticals Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -12.15. This coverage rate is greater than that of merely 7.05% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -67% |
| 1% | -67% |
| 2% | -66% |
| 3% | -66% |
| 4% | -66% |
| 5% | -65% |
ABC, EDAP, WST, ABT, and AZN can be thought of as valuation peers to CPIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...